GENEXINE, INC. |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 7,350 KRW | -0.41% |
|
+4.40% | -25.76% |
| Sales 2022 | 16.14B 11.73M | Sales 2023 | 4.43B 3.22M | Capitalization | 410B 298M |
|---|---|---|---|---|---|
| Net income 2022 | -55.97B -40.69M | Net income 2023 | -66.87B -48.62M | EV / Sales 2022 | 33 x |
| Net Debt 2022 | 62.14B 45.18M | Net Debt 2023 | 2.94B 2.14M | EV / Sales 2023 | 93.4 x |
| P/E ratio 2022 |
-8.34
x | P/E ratio 2023 |
-5.99
x | Employees | 98 |
| Yield 2022 * |
-
| Yield 2023 |
-
| Free-Float | 79.4% |
More Fundamentals
* Assessed data
More news
More press releases
More news
| 1 day | -0.41% | ||
| 1 week | +4.40% | ||
| Current month | -15.52% | ||
| 1 month | -19.32% | ||
| 3 months | -17.14% | ||
| 6 months | -8.01% | ||
| Current year | -25.76% |
1 week
6 900.00
7 490.00
1 month
6 840.009 360.00
Current year
6 840.0010 400.00
1 year
6 840.0013 480.00
3 years
6 840.00100 769.23
5 years
6 840.00146 384.62
10 years
6 840.00146 384.62
| Managers | Title | Age | Since |
|---|---|---|---|
Jung-Won Woo
CEO | Chief Executive Officer | 64 | 21-08-31 |
Young-Chul Sung
FOU | Founder | 67 | 99-06-07 |
Neil Warma
CEO | Chief Executive Officer | 61 | 22-03-29 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Young-Jin Kim
BRD | Director/Board Member | 67 | 15-03-19 |
Peter N. Laivins
BRD | Director/Board Member | 66 | - |
Young-Chul Sung
FOU | Founder | 67 | 99-06-07 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.00% | 7 M€ | +1.70% | - | |
| 0.00% | 4 M€ | -4.41% | - | |
| 0.00% | 117 M€ | +0.68% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-24 | 7,350 | -0.41% | 74 755 |
| 24-04-24 | 7,380 | +1.51% | 66,291 |
| 24-04-23 | 7,270 | +0.14% | 55,897 |
| 24-04-22 | 7,260 | +3.12% | 91,968 |
| 24-04-19 | 7,040 | -1.54% | 98,987 |
End-of-day quote Korea S.E., April 24, 2024
More quotes
Genexine Inc is a Korea-based company mainly engaged in the research and development of bio pharmaceuticals. The Company operates its business through two segments. The New Drug Development segment engages in human growth hormone, neutropenia treatment, anemia treatment, anticancer immunotherapy, hyFc platform, and other technology transfers. In addition, this segment sells the technical property rights of follicle-stimulating hormone. It also engages in cell line construction and sample production, project development, animal testing, human growth hormone development, and government agency research. The Medical Consumables segment produces and sells medical consumables such as medicine bags.
Calendar
2024-05-12
- Q1 2024 Earnings Release (Projected)
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -25.76% | 222M | |
| -3.12% | 104B | |
| +0.87% | 97.42B | |
| +0.79% | 22.2B | |
| -17.86% | 21.23B | |
| -11.11% | 18.33B | |
| -42.83% | 16.35B | |
| -16.15% | 15.06B | |
| +3.62% | 13.98B | |
| +33.85% | 11.66B |
- Stock Market
- Equities
- A095700 Stock
